Analysis of Endotoxin Activity in Patients With ECMO

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-08-21

Study Completion Date

2021-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Extra-corporeal membrane oxygenation (ECMO) can temporarily help patients gain time to wait for cardiopulmonary recovery or further treatment in patients with cardiopulmonary failure. Whether the blood flow provided by the ECMO can maintain the perfusion of various organs is an important factor affecting survival. Some ECMO patients died after the complication of sepsis. Our previous pilot analysis has recognized several ECMO patients with complicated sepsis has high endotoxin activity level. Endotoxemia can also occur in heart surgery and after cardiopulmonary bypass, trauma, organ transplantation, and out-of-hospital cardiac arrest patients. These trials used endotoxin activity analysis (EAA, EAATM, Spectral Diagnostics Inc., Canada) to analyze endotoxin activity. In addition, studies have indicated that the combination of procalcitonin (PCT) concentration and EAA activity can improve the accuracy of predicting sepsis. The primary aim of this study is to detect endotoxin activity in patients with ECMO support and compare whether the prognosis was associated with different level of EAA activity. The secondary aims are to analyze the risk factors leading to high EAA activity and investigate the diagnostic value of septic shock combining PCT examination. We suggest that the results of this study may help the ECMO medical team identify patients at high risk for septic shock and conduct adequate managements to improve patient survival and quality of life after survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Extracorporeal Membrane Oxygenation in Severe Poisoning

NCT05762029

Poison;Medicinal Extracorporeal Membrane Oxygenation

RECRUITING

Cross-sectional Survey of Zhejiang ECMO Application

NCT04979325

Extracorporeal Membrane Oxygenation Cardiopulmonary Resuscitation Epidemiology

UNKNOWN

Extracorporeal Membrane Oxygenation in Coronavirus Disease (COVID-19), Influenza and ARDS of Other Ethiologies

NCT05353725

ARDS COVID-19 Influenza

COMPLETED

ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS

NCT05080933

ARDS COVID-19 H1N1 Influenza

COMPLETED

Estimation of Outcome and Quality of Life in ECMO Patients

NCT06400797

Extracorporeal Membrane Oxygenation

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Shock Respiratory Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ECMO patients

Patients with ECMO support

Extra-corporeal membrane oxygenation

Intervention Type DEVICE

Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extra-corporeal membrane oxygenation

Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with ECMO support

Exclusion Criteria

* \< 20 years old or \> 90 years old
* not be able to collect blood sample within 48 hours after placement of ECMO
* change plan to palliative care and plan to remove ECMO
* non-native speakers

Minimum Eligible Age

20 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No